HCA Healthcare Reports Strong 2025 Financials, Authorizes New $10 Billion Share Repurchase Program, and Increases Quarterly Dividend
HCA sits 70% above its 52-week low of $295.
Summary
HCA Healthcare reported strong financial results for 2025, including a 7.1% revenue increase and 28.8% diluted EPS growth. The company authorized a new $10 billion share repurchase program and increased its quarterly dividend to $0.78 per share.
Key Events · Earnings and Guidance · HCA
-
Strong 2025 Financial Performance
HCA Healthcare reported a 7.1% increase in revenues to $75.600 billion, a 17.8% rise in net income attributable to HCA Healthcare, Inc. to $6.784 billion, and a 28.8% increase in diluted earnings per share to $28.33 for the fiscal year ended December 31, 2025.
-
New $10 Billion Share Repurchase Authorization
The Board of Directors authorized a new $10 billion share repurchase program in January 2026, following the completion of a prior $6 billion authorization in 2025 and significant repurchases of $10.067 billion in 2025.
-
Quarterly Dividend Increase
The company declared an increased quarterly dividend of $0.78 per share on January 26, 2026, up from $0.72 per share in 2025, reflecting an 8.3% increase.
-
Operational Growth and Efficiency
Consolidated admissions increased by 2.7% and equivalent admissions by 2.9% in 2025. The company also saw improved efficiency with salaries and benefits as a percentage of revenues decreasing to 43.5% from 44.1%.
Analysis · HCA · Industrial Applications And Services
HCA Healthcare's annual 10-K filing reveals robust financial performance for 2025, with significant increases in revenue, net income, and diluted EPS. The company's Board of Directors has authorized a substantial new $10 billion share repurchase program, demonstrating a strong commitment to returning capital to shareholders. Additionally, the quarterly dividend has been increased, signaling confidence in future cash flows. While the filing details ongoing regulatory challenges and the impact of the Federal Budget Act of 2025, the overall financial strength and proactive capital allocation strategy are highly positive for investors. The Frist family's share exchange, a tax-free reorganization, is a notable but non-operational event for a major shareholder.
At the time of this filing, HCA was trading at $502.05 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $114.5B. The 52-week trading range was $295.00 to $527.55. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.